BRIEF—Fuji Chemical takes over rights to Ulcerlmin

Japan’s Chugai Pharmaceutical and Fuji Chemical Industries have entered into a business transfer agreement for Ulcerlmin (sucralfate hydrate) for the treatment of gastritis/peptic ulcer, now manufactured and marketed by Chugai.

Ulcerlmin, created and developed by Chugai, which is majority-owned by Roche, has been launched in Japan since 1968.

Currently, the drug is approved in more than 30 countries and has contributed to treatment for many patients in Japan and other countries.

Based on the agreement, the rights related to supply of drug substances to overseas manufacturing and sales companies of Ulcerlmin and the rights related to the marketing authorization of the drug in Japan, will be devolved to Fuji Chemical Industries from Chugai on April 1, 2019 and by September 30, 2019, respectively.

For Japanese market, after the succession of the Ulcerlmin business, distribution of the products manufactured by Chugai will continue for a certain period to ensure stable supply of the drug.